Why Devi Shetty Says It’s Not Wrong To Charge Rich Patients More
India's top cardiac surgeon said differentiated pricing of healthcare services for the rich and the poor is the only way the industry can function effectively even as the government clamps down on high-cost stents and knee implants.
A majority of hospitals in India cross-subsidise the poor by overcharging the rich in return for “personalised”, “priority” services, Dr Devi Shetty, chairman of Bengaluru-based Narayana Hrudayalaya, told BloombergQuint.
That comes as a debate rages about how much private hospitals should charge for their services. Parents of a seven-year-old girl, who died of dengue at a Fortis Group hospital in Gurugram, were charged up to 1,700 percent mark-up on medical equipment and drugs.
Conceding that such isolated incidents invited restrictions on the healthcare industry, Shetty said, “We charge the rich and subsidise the poor.”
That's the only way a country like India can offer healthcare to the masses...The government can fix any price but then it should be paying for what it actually costs. Which they are not doing.Dr Devi Shetty, Cardiologist & Chairman, Narayana Hrudayalaya
Removing the concept of cross-subsidy will result in poor people paying more and the rich paying less, he cautioned. “We just want 40 percent of the people to pay a premium price for occupying single rooms with all the luxuries. In the process, most private hospitals in Karnataka offer 20 percent of services to government scheme patients and charge only 30-40 percent of what it costs to do the operation. They write off 60 percent,” he said explaining the business model of Narayana Hrudayalaya and other private hospitals.
The middle ground is for the government to fix an MRP which is “fair to patients, manufacturers and hospitals”, he said.
Also Read: Stent Price Cap Turns Away The Rich Patient On Whom Healthcare Survives: Devi Shetty
You can watch the full interview here.
Also Read: No Mid-Term Revision Of Stent Prices Before February 2018, Says Drug Pricing Regulator
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.